ARQ 092 – Proteus Trial Design

- On-going NIH sponsored Phase 1 study
  - A 3+3 Phase 1 dose escalation design
  - Continuous dosing based on preclinical and oncology clinical data
  - Safety and percent inhibition of p-AKT will be analyzed after completion of each dose level prior to determining the need for a dose escalation to the next dose level
- Objectives
  - Safety and tolerability
  - Tissue p-AKT inhibition and ARQ 092 concentration
  - Change in Proteus syndrome symptoms
    - Imaging
    - Photography
    - Quality of life and patient reported physical functioning

Phase 1 trial enrolling

Orphan drug designation granted by FDA

Proteus Trial – First Cohort Data

- Demographics
  - Three adult males dosed
- Dosing
  - All three patients dosed with ARQ 092 at lowest dose as determined by the protocol
  - Dosing continues at lowest dose
- Data
  - Protocol defined pre-specified decrease of at least 50% in AKT signaling was achieved in all three patients on biopsies at days 15 and 75
  - Pharmacokinetic profile similar to ARQ 092 in oncology
  - Safety profile acceptable

Next Steps:

- NIH to enroll second cohort with patients ages 12 to 18

AKT knockdown achieved in first cohort